摘要
钠-葡萄糖协同转运蛋白2抑制剂是一种新型的降糖药物,其抑制钠-葡萄糖协同转运蛋白2的作用机制不同于以往的降血糖药物,已被证明可降低患有或处于心血管疾病高风险的2型糖尿病患者发生心力衰竭住院的风险。关于钠葡萄糖协同转运蛋白2抑制剂减少糖尿病患者心血管死亡和事件的报道已引起了心脏病学领域的关注。现就钠-葡萄糖协同转运蛋白2抑制剂对2型糖尿病致心力衰竭患者的心血管保护和心血管事件危险因素的预防机制做一综述。
Sodium glucose cotransporter 2 inhibitor is a new type of hypoglycemic drug.Its mechanism of inhibiting sodium glucose cotransporter 2 is different from the previous hypoglycemic drugs.It has been proved that it can reduce the risk of heart failure hospitalization in type 2 dia-betes patients with or at high risk of cardiovascular disease.Reports that natriuretic glucose cotransporter-2 inhibitors reduce cardiovascular death and events in diabetic patients have attracted much attention in the field of Cardiology.This article reviews the cardiovascular protection of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes heart failure and the prevention mechanism of cardiovascular event risk factors.
作者
赵胜玲
莫霄云
黄琛
黄金琳
ZHAO Shengling;MO Xiaoyun;HUANG Chen;HUANG Jinlin(College of Internal Chinese Medicine,Guangxi University of Chinese Medicine,Nanning,Guangxi,530001,China;Department of Cardiology,The First Affiliated Hospital of Guangxi University of Chinese Medicine,Nanning,Guangxi,530001,China)
出处
《当代医学》
2023年第30期189-194,共6页
Contemporary Medicine
基金
广西中医药大学校级科研项目(2019MS017)。
